SARS-CoV-2 pre-exposure prophylaxis with tixagevimab/cilgavimab (AZD7442) provides protection in inborn errors of immunity with antibody defects: a real-world experience

BACKGROUND: Preventive strategies against severe COVID-19 in Inborn Errors of Immunity (IEI) include bivalent vaccines, treatment with SARS-CoV-2 monoclonal antibodies (mAbs), early antiviral therapies, and pre-exposure prophylaxis (PrEP). OBJECTIVE: To assess the effectiveness of the PrEP with tixa...

Descripción completa

Detalles Bibliográficos
Autores principales: Pulvirenti, Federica, Garzi, Giulia, Milito, Cinzia, Sculco, Eleonora, Sciannamea, Maddalena, Napoli, Anna, Cinti, Lilia, Roberto, Piergiorgio, Punziano, Alessandra, Carrabba, Maria, Piano Mortari, Eva, Carsetti, Rita, Antonelli, Guido, Quinti, Isabella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639167/
https://www.ncbi.nlm.nih.gov/pubmed/37954618
http://dx.doi.org/10.3389/fimmu.2023.1249462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10639167/
https://www.ncbi.nlm.nih.gov/pubmed/37954618
http://dx.doi.org/10.3389/fimmu.2023.1249462

Ejemplares similares